Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue: 2020-2024

Historic Current Deferred Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Dec 2024 value amounting to $288,000.

  • Viridian Therapeutics, Inc.\DE's Current Deferred Revenue changed negligibly% to $288,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $288,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $288,000 for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Current Deferred Revenue of $288,000 as of FY2024, which was down 0.00% from $288,000 recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Current Deferred Revenue registered a high of $301,000 during FY2020, and its lowest value of $288,000 during FY2022.
  • Its 3-year average for Current Deferred Revenue is $288,000, with a median of $288,000 in 2024.
  • Data for Viridian Therapeutics, Inc.\DE's Current Deferred Revenue shows a maximum YoY fell of 3.99% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Current Deferred Revenue stood at $301,000 in 2020, then fell by 3.99% to $289,000 in 2021, then decreased by 0.35% to $288,000 in 2022, then remained steady at $288,000 in 2023, then remained steady at $288,000 in 2024.